Caprion

Finding proteins that hit the mark

Biomarker Discovery

IDENTIFYING BIOLOGICALLY AND CLINICALLY RELEVANT BIOMARKERS

  • Expertise in sample prep, mass spectrometry and bioinformatics
  • Option for both unbiased and targeted discovery
  • Off-the-shelf and customized targeted protein panels
  • Positive, mass spec-based protein identification

Learn more

Fit-for-Purpose Assays

TRANSLATING DISCOVERIES INTO ROBUST ASSAYS

  • Qualification and validation of biomarker assays
  • Multiplexed, highly specific mass-spec based assays
  • Rapid development of custom biomarker panels
  • Validation of protein biomarkers from multi-omics discovery

Learn more

Bioanalytical Services

SOLUTIONS FOR CHARACTERIZATION OF BIOTHERAPEUTICS

  • Development and deployment of highly specific mass spec assays
  • Discovery and quantitation of individual host cell proteins
  • Development, qualification and validation of assays for PK/PD
  • Regulatory expertise, GLP and GCLP capabilities

Learn more

Clinical Diagnostic Assays

BIOMARKER PANELS FOR ASSESSING DISEASE AND TREATMENT RESPONSE

  • Pancreatic islet biomarkers to monitor beta cell function and assess therapeutic benefit in Diabetes
  • Biomarkers to distinguish active from latent Tuberculosis
  • Clinically validated Lung Xpresys™ test for differentiating benign from malignant lung nodules

Learn more

Strategic Partners & Alliances

  • National Institute of Allergy and Infectious Diseases

    NIAID funds the Caprion Clinical Protemoics Center for infectious disease research

  • Québec Consortium for Drug Discovery

    The Québec Consortium for Drug Discovery initiated a projects to develop biomarkers for measurment of early stage diabetes disease and therapy response prediction.

    CQDM.org
    Corporate Video

© 2015 Caprion